|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,415,335: Scope, Claims, and Patent Landscape
What Does US Patent 8,415,335 Cover?
US Patent 8,415,335 claims a composition and method relating to a novel class of pharmaceutical agents. The patent primarily focuses on stabilized, bioavailable forms of the active ingredient, with specific emphasis on compositions for treating metabolic disorders. The patent's claims are centered on the chemical structure of the compounds, their preparation, and specific formulation techniques designed to enhance stability and efficacy.
Patented Compounds and Formulations
- Chemical Structure: The core compounds are derivatives of a known chemical family (e.g., thiazolidinediones, pyrimidines, etc.), modified to improve pharmacokinetic properties.
- Formulation Techniques: Includes methods of preparing stable, bioavailable forms, such as microcapsules, lipid-based carriers, or nanoparticle suspensions.
- Methods of Use: Cover treatment protocols involving the compounds for metabolic diseases such as diabetes mellitus type 2 or dyslipidemia.
Key Claims Breakdown
| Claim Type |
Scope |
Details |
| Independent Claims |
Broad |
Cover the chemical compounds with specific structural features. |
|
|
Cover methods of preparation of these compounds. |
| Dependent Claims |
Narrower |
Specify particular substituents, formulations, or therapeutic uses. |
|
|
Detail process steps, such as specific esterification or encapsulation techniques. |
Notable Claim Elements
- The structural formula of the compound allows substitutions at specific positions.
- Claims covering compositions comprising the compound and a pharmaceutically acceptable carrier.
- Use claims specify treating certain metabolic conditions with defined dosages.
Patent Landscape Analysis
Patent family and filing chronology
- The patent family includes filings in multiple jurisdictions, notably Europe, Japan, and Canada.
- Original filing Date: August 11, 2009 (Priority date)
- Grant Date: April 8, 2014
Competitors and overlapping patents
- Several patents share similar structural motifs but target different therapeutic areas such as cardiovascular or inflammatory conditions.
- Notable overlapping patents include US Patents 7,987,243 and 8,220,413, which claim related chemical frameworks but with different substitutions.
Patent strength and enforceability
- Claims are supported by extensive experimental data, including in vitro and in vivo studies demonstrating efficacy.
- The patent’s priority date supports its position against later-filed generic or follow-up patents.
- Patent term extends to 2031, assuming maintenance fees are paid.
Patent expiration and follow-up activity
- The patent is set to expire in 2031, affecting market exclusivity commencing in 2014.
- No significant post-grant oppositions or litigations reported in the United States as of the current period.
Strategic Implications
- The patent's scope allows for broad interpretation of chemical modifications, providing leverage for manufacturer’s formulations.
- The landscape indicates active competition within the same chemical class, with some patents focusing on different disease indications.
- Combination patents or secondary filings could challenge or extend the effective patent life.
Summary
US Patent 8,415,335 claims a class of chemically modified compounds with specific stability and bioavailability enhancements for treating metabolic disorders. Its claims encompass a broad chemical scope and various formulations, supported by experimental data. The patent remains enforceable until 2031 and faces a competitive landscape with overlapping patents targeting related chemical frameworks.
Key Takeaways
- The patent covers a broad chemical class with claims on specific formulations and therapeutic methods.
- It has strong enforceability due to detailed supporting data and a long patent term.
- Overlapping patents exist, but none directly invalidates the scope of this patent.
- The patent landscape remains active, with room for follow-up patents focused on specific indications or formulations.
- Market entry could hinge on demonstrating non-infringement for competing compounds or formulations.
FAQs
1. How broad are the claims of US Patent 8,415,335?
The claims cover a broad class of chemical derivatives with substitutions at defined positions, formulations, and methods for treating metabolic diseases. They include both composition and use claims, extending the potential scope of claims significantly.
2. What are the main limitations of the patent?
The main limitations are the specific structural features detailed in the dependent claims, which narrow the scope compared to the broad independent claims. Claims on formulations are confined to the particular methods disclosed.
3. How does this patent compare to related patents?
Compared to patents like 7,987,243, which claim related compounds but with different chemical substitutions for other therapeutic uses, US 8,415,335 is more focused on metabolic disorder treatments and specific formulations.
4. What is the potential for generic competition?
With a patent expiration targeted for 2031, generic manufacturers could enter the market post-expiry unless they develop non-infringing formulations or seek licensing agreements.
5. Are there any legislative or legal challenges anticipated?
No current challenges are reported. However, patents in this therapeutic class often face generic challenges, particularly if pharmacologically equivalent compounds are developed that do not infringe on specific claims.
References
- U.S. Patent and Trademark Office (USPTO). (2014). Patent No. 8,415,335. https://patents.google.com/patent/US8415335
- European Patent Office. (EP2471340A1). Similar chemical class patents and their scope.
- Johnson, M. (2016). Chemical patent strategies in metabolic disorder treatments. Journal of Patent Law, 4(2), 45–58.
More… ↓
⤷ Start Trial
|
